Real-World Treatment Patterns for Lung Neuroendocrine Tumors

A Claims Database Analysis

Michael S. Broder, Beilei Cai, Eunice Chang, Maureen P. Neary, Elya Papoyan, Al B Benson III

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The aim of this study was to describe real-world lung neuroendocrine tumor (NET) treatment patterns. Methods: This study examined cytotoxic chemotherapy (CC), somatostatin analogues (SSA), targeted therapy (TT), interferon, and liver-directed therapies in 2 US claims databases. Patients ≥18 years with ≥1 inpatient or ≥2 outpatient claims for lung NET, initiating pharmacologic treatment between July 1, 2009, and June 30, 2014, were identified and followed until the end of enrollment or study end, whichever occurred first. Results: A total of 785 newly pharmacologically treated lung NET patients were identified: Mean (SD) age was 58.6 (9.1) years; 54.0% were female; 78.2% started first-line therapy with CC, 18.1% with SSA, and 1.1% with TT. Mean duration of first-line treatment was 397 days for SSA, 142 days for CC, and 135 days for TT. 74.1% of patients received no pharmacological treatment beyond first-line. The most common second-line treatment was SSA. Conclusions: Most patients received CC as first-line treatment, with SSA being less common. SSA-treated patients remained on therapy for > 1 year, compared to < 5 months for CC. The high proportion of patients using chemotherapy and the low proportion receiving second-line treatment seems consistent with treatment guidelines for small cell lung cancer rather than for NET. Future studies are warranted to describe reasons for treatment choice, discontinuation, and switching.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalOncology (Switzerland)
Volume94
Issue number5
DOIs
StatePublished - Apr 1 2018

Fingerprint

Insurance Claim Review
Neuroendocrine Tumors
Databases
Lung
Somatostatin
Therapeutics
Drug Therapy
Small Cell Lung Carcinoma

Keywords

  • Chemotherapy
  • Insurance claims
  • Neuroendocrine tumor
  • Somatostatin analogue

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Broder, Michael S. ; Cai, Beilei ; Chang, Eunice ; Neary, Maureen P. ; Papoyan, Elya ; Benson III, Al B. / Real-World Treatment Patterns for Lung Neuroendocrine Tumors : A Claims Database Analysis. In: Oncology (Switzerland). 2018 ; Vol. 94, No. 5. pp. 281-288.
@article{9c122b5b17b7420a88bdf8421126dbe3,
title = "Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis",
abstract = "Objective: The aim of this study was to describe real-world lung neuroendocrine tumor (NET) treatment patterns. Methods: This study examined cytotoxic chemotherapy (CC), somatostatin analogues (SSA), targeted therapy (TT), interferon, and liver-directed therapies in 2 US claims databases. Patients ≥18 years with ≥1 inpatient or ≥2 outpatient claims for lung NET, initiating pharmacologic treatment between July 1, 2009, and June 30, 2014, were identified and followed until the end of enrollment or study end, whichever occurred first. Results: A total of 785 newly pharmacologically treated lung NET patients were identified: Mean (SD) age was 58.6 (9.1) years; 54.0{\%} were female; 78.2{\%} started first-line therapy with CC, 18.1{\%} with SSA, and 1.1{\%} with TT. Mean duration of first-line treatment was 397 days for SSA, 142 days for CC, and 135 days for TT. 74.1{\%} of patients received no pharmacological treatment beyond first-line. The most common second-line treatment was SSA. Conclusions: Most patients received CC as first-line treatment, with SSA being less common. SSA-treated patients remained on therapy for > 1 year, compared to < 5 months for CC. The high proportion of patients using chemotherapy and the low proportion receiving second-line treatment seems consistent with treatment guidelines for small cell lung cancer rather than for NET. Future studies are warranted to describe reasons for treatment choice, discontinuation, and switching.",
keywords = "Chemotherapy, Insurance claims, Neuroendocrine tumor, Somatostatin analogue",
author = "Broder, {Michael S.} and Beilei Cai and Eunice Chang and Neary, {Maureen P.} and Elya Papoyan and {Benson III}, {Al B}",
year = "2018",
month = "4",
day = "1",
doi = "10.1159/000486282",
language = "English (US)",
volume = "94",
pages = "281--288",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

Real-World Treatment Patterns for Lung Neuroendocrine Tumors : A Claims Database Analysis. / Broder, Michael S.; Cai, Beilei; Chang, Eunice; Neary, Maureen P.; Papoyan, Elya; Benson III, Al B.

In: Oncology (Switzerland), Vol. 94, No. 5, 01.04.2018, p. 281-288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Real-World Treatment Patterns for Lung Neuroendocrine Tumors

T2 - A Claims Database Analysis

AU - Broder, Michael S.

AU - Cai, Beilei

AU - Chang, Eunice

AU - Neary, Maureen P.

AU - Papoyan, Elya

AU - Benson III, Al B

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Objective: The aim of this study was to describe real-world lung neuroendocrine tumor (NET) treatment patterns. Methods: This study examined cytotoxic chemotherapy (CC), somatostatin analogues (SSA), targeted therapy (TT), interferon, and liver-directed therapies in 2 US claims databases. Patients ≥18 years with ≥1 inpatient or ≥2 outpatient claims for lung NET, initiating pharmacologic treatment between July 1, 2009, and June 30, 2014, were identified and followed until the end of enrollment or study end, whichever occurred first. Results: A total of 785 newly pharmacologically treated lung NET patients were identified: Mean (SD) age was 58.6 (9.1) years; 54.0% were female; 78.2% started first-line therapy with CC, 18.1% with SSA, and 1.1% with TT. Mean duration of first-line treatment was 397 days for SSA, 142 days for CC, and 135 days for TT. 74.1% of patients received no pharmacological treatment beyond first-line. The most common second-line treatment was SSA. Conclusions: Most patients received CC as first-line treatment, with SSA being less common. SSA-treated patients remained on therapy for > 1 year, compared to < 5 months for CC. The high proportion of patients using chemotherapy and the low proportion receiving second-line treatment seems consistent with treatment guidelines for small cell lung cancer rather than for NET. Future studies are warranted to describe reasons for treatment choice, discontinuation, and switching.

AB - Objective: The aim of this study was to describe real-world lung neuroendocrine tumor (NET) treatment patterns. Methods: This study examined cytotoxic chemotherapy (CC), somatostatin analogues (SSA), targeted therapy (TT), interferon, and liver-directed therapies in 2 US claims databases. Patients ≥18 years with ≥1 inpatient or ≥2 outpatient claims for lung NET, initiating pharmacologic treatment between July 1, 2009, and June 30, 2014, were identified and followed until the end of enrollment or study end, whichever occurred first. Results: A total of 785 newly pharmacologically treated lung NET patients were identified: Mean (SD) age was 58.6 (9.1) years; 54.0% were female; 78.2% started first-line therapy with CC, 18.1% with SSA, and 1.1% with TT. Mean duration of first-line treatment was 397 days for SSA, 142 days for CC, and 135 days for TT. 74.1% of patients received no pharmacological treatment beyond first-line. The most common second-line treatment was SSA. Conclusions: Most patients received CC as first-line treatment, with SSA being less common. SSA-treated patients remained on therapy for > 1 year, compared to < 5 months for CC. The high proportion of patients using chemotherapy and the low proportion receiving second-line treatment seems consistent with treatment guidelines for small cell lung cancer rather than for NET. Future studies are warranted to describe reasons for treatment choice, discontinuation, and switching.

KW - Chemotherapy

KW - Insurance claims

KW - Neuroendocrine tumor

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=85043472331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043472331&partnerID=8YFLogxK

U2 - 10.1159/000486282

DO - 10.1159/000486282

M3 - Article

VL - 94

SP - 281

EP - 288

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 5

ER -